AT1 FY21 - General Discussion + FA, page-1698

LDX FY21 Results call just finished. There were several good Qs asked by various folks (incl. one from me) - posting FebriDx related info; interestingly the Q&A function was kept open so any posted QnA could be seen by all)
-----------------------------------------------------

Q) Considering the forward looking statement in today's Results presentation, "Lumos does not believe...Covid19 related demand is likely to continue..expecting...number of dev programs..by Commercial Services..will return to pre-Covid growth...", why are you planning to launch ViraDx product with Covid19 multiplex testing?

(typed reply) The forward looking statement relates to demandfor development services programs for clients specifically as opposed toongoing demand for products like ViraDx.

Q) Can you please describe the markets where you feel that FebriDx use is closest to its intended use in primary care? For instance if we look at the three markets you called out: UK, Germany and Canada can you describe the clinical settings that are picking the product up?

(live reply; paraphrased) initially the take-up was in clinical settings but this has expanded to worksites, commercial biz and clinical settings also continue. Also seeing regular take-up for Covid19 related complementary testing etc.

Q) What is the current annual FebriDx test manufacture capacity or is this capacity included in the 10m/month expansion already completed?

(typed reply) It is included within the 10m per month totalmanufacturing capacity

Q) As the FebriDx device platform is sourced from another company (Atomo Diagnostics) and considering the growth potential, post US FDA approval, how are you managing any supply chain risks eg: locking an annual supply agreement with Atomo or bringing e2e production in-house?
(live reply; paraphrased) Well aware of the initial supply chain risks; LDX proactively stockpiled inventory in anticipation of the requirements post FDA approval; also in close contact with Atomo Diagnostics to ensure regular forecasting & device supply
-----------------------------------------------------